The drug garnered $5.3 billion in sales in the first half of this year, reflecting a 35% y-o-y growth. Not only did Regeneron see its sales rise, but it also expanded its operating margin from 28.1% in 2019 to 39.9% in 2022. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care. For investors keen on capturing this intersection's potential, several publicly traded companies are making significant strides in embedding AI into their operations. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

Key Data

The technique has proven to be very useful for finding positive surprises. Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat. Lead drug Eylea has global sales around $9 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned, as its high-dose formulation should allow it to continue to hold strong market share against biosimilars and Roche's new branded drug, Vabysmo.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

• After its recent rise, REGN stock looks like it has little room for growth.
• The monthly returns are then compounded to arrive at the annual return.
• REGN’s beta can be found in Trading Information at the top of this page.
• You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with https://1investing.in/ an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

Regeneron Pharmaceuticals Inc. Past Events

Regeneron saw its sales rise in recent years, led by its Covid-19 multi-antibody therapy, which garnered $6 billion in 2021 sales. Another contributor to its top-line growth is Eylea, garnering $6.3 billion in 2022. It is also used to treat diabetic eye disease and other retina problems. With its recent approval of a high-dose version of Eylea, sales will likely grow faster. However, Eylea could face biosimilar competition as early as next year. The company has another blockbuster drug - Dupixent (co-markets with Sanofi) - a treatment for eczema.

After its recent rise, REGN stock looks like it has little room for growth. It trades at 13x revenues compared to its last five-year average of 9x. Our Regeneron Valuation Ratios Comparison dashboard market makers in india has more details. Given the uptick in Dupixent sales, a slight upward revision in the sales multiple looks justified. That said, at its current level of $820, the positives appear to be priced in.

Undervalued Biotech Stocks for 2023

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Interestingly, REGN stock has had a Sharpe Ratio of 0.5 since early 2017, slightly lower than 0.6 for the S&P 500 Index over the same period.

Regeneron Pharmaceuticals Estimates* in EUR

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%.

This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Compare REGN’s historical performance against its industry peers and the overall market. REGN’s beta can be found in Trading Information at the top of this page.

This 120% rise for Regeneron stock since late 2019 can primarily be attributed to 1. The company’s P/S ratio rising 50% to 12.6x revenues vs. 8.4x in 2019, 2. Regeneron’s revenue growth of 44% to $6.9 billion over the last twelve months, compared to $4.8 billion in 2019, and 3. This has meant that the company’s revenue per share metric has risen 46% to $65.02 now, compared to $44.60 in 2019.

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. We’d like to share more about how we work and what drives our day-to-day business. Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of REGN’s competitive advantage.

Markets

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.